Helicobacter pylori is recognized as a major cause of gastritis, peptic ulcer, gastric cancer, and mucosa-associated lymphoma. Infection with this gram-negative microaerophile has been treated using combination of antibiotics and proton pump inhibitors for different gastrointestinal diseases. The most commonly used treatment is triple therapy which consists of administration of a proton pump inhibitor, clarithromycin, and amoxicillin. Many factors contribute to treatment failure, but one of the main reasons is development of bacterial antibiotic resistance. The percent prevalence of antibiotic resistance varies among different countries; it appears to be partly determined by the geographic factors and its ability to undergo frequent homolog...
AbstractIn developing countries, clarithromycin resistance and frequency of re-infection are factors...
Helicobacter pylori which is one of the commonly seen chronic bacterial infections in the world, has...
BACKGROUND & AIMS: In 2017, the World Health Organization (WHO) designated clarithromycin-resist...
Background: Establishing effective and acceptable treatment regimens for patients infected with Heli...
There are no generally accepted regimens for the treatment of H. pylori infection in patients with g...
BACKGROUND: Helicobacter pylori is the etiological agent for diseases ranging from chronic gastritis...
Helicobacter pylori is a Gram-negative, spiral shaped bacterium that colonizes the epithelial mucosa...
Resistance of Helicobacter pylori (HP) to metronidazole (MTZ) is a growing medical problem in variou...
AbstractObjectivesTo determine the prevalence of Helicobacter pylori ureA and clarithromycin resista...
Helicobacter pylori (hereinafter referred to as H. pylori) is a gram-negative bacteria which colonis...
Objective: The aim of this research work is to assess the occurrence and antibiotic resistance among...
Helicobacter pylori is an important human pathogen that colonises the stomach of about half of the w...
Background/Aim: Helicobacter pylori is an important pathogen for gastroduodenal diseases. Infection ...
Background: Helicobacter pylori is the etiological agent for diseases ranging from chronic gastritis...
Background and purpose : -Helicobacter pylori is a gram negative spiral bacilus which infects gastri...
AbstractIn developing countries, clarithromycin resistance and frequency of re-infection are factors...
Helicobacter pylori which is one of the commonly seen chronic bacterial infections in the world, has...
BACKGROUND & AIMS: In 2017, the World Health Organization (WHO) designated clarithromycin-resist...
Background: Establishing effective and acceptable treatment regimens for patients infected with Heli...
There are no generally accepted regimens for the treatment of H. pylori infection in patients with g...
BACKGROUND: Helicobacter pylori is the etiological agent for diseases ranging from chronic gastritis...
Helicobacter pylori is a Gram-negative, spiral shaped bacterium that colonizes the epithelial mucosa...
Resistance of Helicobacter pylori (HP) to metronidazole (MTZ) is a growing medical problem in variou...
AbstractObjectivesTo determine the prevalence of Helicobacter pylori ureA and clarithromycin resista...
Helicobacter pylori (hereinafter referred to as H. pylori) is a gram-negative bacteria which colonis...
Objective: The aim of this research work is to assess the occurrence and antibiotic resistance among...
Helicobacter pylori is an important human pathogen that colonises the stomach of about half of the w...
Background/Aim: Helicobacter pylori is an important pathogen for gastroduodenal diseases. Infection ...
Background: Helicobacter pylori is the etiological agent for diseases ranging from chronic gastritis...
Background and purpose : -Helicobacter pylori is a gram negative spiral bacilus which infects gastri...
AbstractIn developing countries, clarithromycin resistance and frequency of re-infection are factors...
Helicobacter pylori which is one of the commonly seen chronic bacterial infections in the world, has...
BACKGROUND & AIMS: In 2017, the World Health Organization (WHO) designated clarithromycin-resist...